Drugs Control Administration (DCA), Telangana, seized 'Pleehamrutha Syrup', an Ayurvedic drug, from a medical shop in Kukatpally, Medchal-Malkajgiri District, for its misleading advertisement for the cure of chronic fevers and typhoid fevers. This has been done under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, against misleading advertisements of drugs for the cure of certain diseases and disorders.

Key Highlights:
Misleading Advertisement Violation:

• The product label misrepresented that it cures 'Chronic Fevers & Typhoid Fevers', an offense under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

• The act prohibits advertising drugs for the cure of some specified diseases and disorders.

Manufacturing and Marketing Details:

• Manufactured by: Ravi Varma Ayur & Herbal Remedies, Vizianagaram, Andhra Pradesh.

• Marketed by: Panchaprana Herbal Remedies, Vizianagaram, Andhra Pradesh.

Seizure and Investigation:

• DCA officials seized 'Pleehamrutha Syrup' stocks from a medical shop in Kukatpally during a raid on 14 February 2025.

• Investigation is ongoing, and legal action will be initiated against all the culprits.

Legal Consequences for Misleading Advertisements:

• The culprits of making misleading advertisements for drugs can be imprisoned for six months, be fined, or both.

• Reporting of Illegal Drug Manufacturing or Marketing Activities by Public:

• The public can report suspected illegal drug manufacturing or marketing activities by contacting the Telangana DCA Toll-Free Number: 1800-599-6969 (functional between 10:30 AM to 5:00 PM on all working days).

Statements by Officials:
Smt. M. Sreebindu, Drugs Inspector, Kukatpally:
"Advertisement of a medicine to treat chronic fevers and typhoid fevers is prohibited under the Drugs and Magic Remedies Act. Further investigation is on, and suitable legal action will be taken."The enforcement action taken by the DCA against 'Pleehamrutha Syrup' highlights the importance of regulatory intervention in preventing false claims in drug advertising. The public is warned to remain vigilant against false medicinal claims and report suspected violations to the authorities. The DCA remains vigilant in monitoring the market to prevent consumers from being protected from false and potentially harmful medical claims.